secwatch.observer — SEC 8-K summary
======================================

Issuer:     CURIS INC (CRIS)
CIK:        0001108205
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001564590-22-018292
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Curis Q1 net loss $16.1M; cash $120.7M; emavusertib studies on partial clinical hold
--------------------------------------------------------------------------------

- Net loss $16.1M ($0.18/sh) vs $9.9M in Q1 2021; revenue $2.1M unchanged.
- Cash and investments $120.7M; runway into 2024, guidance unchanged.
- FDA partial clinical hold on TakeAim Leukemia and Lymphoma studies for emavusertib due to rhabdomyolysis data request.
- TakeAim Leukemia data: 40% CR/CRh in spliceosome-mutated AML; 57% ORR in spliceosome-mutated MDS.
- CI-8993 (anti-VISTA) dose escalation cleared 0.3mg/kg; now at 0.6mg/kg; RP2D yet to be determined.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1108205/000156459022018292/0001564590-22-018292-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1108205/000156459022018292/cris-8k_20220505.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-018292

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer